{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:20:11Z","timestamp":1783653611412,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanxi Bethune Hospital High-level Talents Introduction Research Fund","award":["2021RC018"],"award-info":[{"award-number":["2021RC018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>A retrospective clinical study was conducted to compare the prognosis between the opioid analgesic (OA) treated and OA-untreated groups and to evaluate the effect of opioid analgesics on the efficacy of immune checkpoint inhibitors (ICIs) in the treatment of advanced lung cancer patients. In addition, a subgroup analysis of the clinical characteristics of the enrolled patients was performed to explore possible influencing factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study reviewed the medical records of eligible patients who received ICIs at our institution. The clinicopathological features and clinical outcomes were compared. Also, the use of OA was collected. Patient survival, the incidence of immune-related adverse events (irAEs), and other baseline variables were examined in both cohorts according to whether OA was used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 132 patients were included in the study. Of them, 39 (29.5%) were in the OA-treated group. No significant differences in baseline characteristics were observed between the OA-treated and untreated groups. The combined application of OA treatment significantly shortened progression-free survival (PFS) (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and overall survival (OS) (<jats:italic>P<\/jats:italic>\u2009=\u20090.002). However, both groups experienced similar incidences and gradations of irAEs. According to multivariate analysis, OA treatment resulted in significantly worse PFS (HR\u2009=\u20094.994, 95% CI 3.217\u20137.753, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and OS (HR\u2009=\u20093.618, 95% CI 2.030\u20136.240, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Clinical outcomes of ICIs were significantly diminished in a cohort of Chinese patients with advanced lung cancer receiving OA therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-022-02210-9","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T07:05:54Z","timestamp":1669014354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiaoyuan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"issue":"10304","key":"2210_CR1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet (London, England). 2021;398(10304):1002\u201314.","journal-title":"Lancet (London, England)"},{"issue":"11","key":"2210_CR2","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2210_CR3","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.immuni.2019.05.023","volume":"50","author":"XV Li","year":"2019","unstructured":"Li XV, Leonardi I, Iliev ID. Gut Mycobiota in Immunity and Inflammatory Disease. Immunity. 2019;50(6):1365\u201379.","journal-title":"Immunity"},{"key":"2210_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120238","volume":"33","author":"S Caballero","year":"2015","unstructured":"Caballero S, Pamer EG. Microbiota-mediated inflammation and antimicrobial defense in the intestine. Annu Rev Immunol. 2015;33:227\u201356.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2210_CR5","doi-asserted-by":"publisher","first-page":"1946368","DOI":"10.1080\/19490976.2021.1946368","volume":"13","author":"A Cruz-Lebr\u00f3n","year":"2021","unstructured":"Cruz-Lebr\u00f3n A, Johnson R, Mazahery C, Troyer Z, Joussef-Pi\u00f1a S, Qui\u00f1ones-Mateu ME, Strauch CM, Hazen SL, Levine AD. Chronic opioid use modulates human enteric microbiota and intestinal barrier integrity. Gut microbes. 2021;13(1):1946368.","journal-title":"Gut microbes"},{"issue":"2&3","key":"2210_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/FBP.0000000000000538","volume":"31","author":"M Ren","year":"2020","unstructured":"Ren M, Lotfipour S. The role of the gut microbiome in opioid use. Behav Pharmacol. 2020;31(2&3):113\u201321.","journal-title":"Behav Pharmacol"},{"key":"2210_CR7","doi-asserted-by":"publisher","first-page":"174284","DOI":"10.1016\/j.ejphar.2021.174284","volume":"906","author":"RA Prasetya","year":"2021","unstructured":"Prasetya RA, Metselaar-Albers M, Engels F. Concomitant use of analgesics and immune checkpoint inhibitors in non-small cell lung cancer: A pharmacodynamics perspective. Eur J Pharmacol. 2021;906:174284.","journal-title":"Eur J Pharmacol"},{"issue":"6371","key":"2210_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"key":"2210_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201360.","journal-title":"Cancer Treat Rev"},{"issue":"6371","key":"2210_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science"},{"issue":"6264","key":"2210_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou M, Pitt JM, Daill\u00e8re R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079\u201384.","journal-title":"Science"},{"key":"2210_CR12","doi-asserted-by":"crossref","unstructured":"Jalodia R, Abu YF, Oppenheimer MR, Herlihy B, Meng J, Chupikova I, Tao J, Ghosh N, Dutta RK,\u00a0Kolli U, Yan Y, Valdes E, Sharma M, Sharma U, Moidunny S, Roy S. Opioid Use, Gut Dysbiosis, Inflammation, and\u00a0the Nervous System. J Neuroimmune Pharmacol. 2022.","DOI":"10.1007\/s11481-021-10046-z"},{"issue":"13","key":"2210_CR13","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1111\/1759-7714.14001","volume":"12","author":"K Miura","year":"2021","unstructured":"Miura K, Sano Y, Niho S, Kawasumi K, Mochizuki N, Yoh K, Matsumoto S, Zenke Y, Ikeda T, Nosaki K, et al. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study. Thoracic cancer. 2021;12(13):1983\u201394.","journal-title":"Thoracic cancer"},{"issue":"5","key":"2210_CR14","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00520-017-3614-y","volume":"25","author":"D Zylla","year":"2017","unstructured":"Zylla D, Steele G, Gupta P. A systematic review of the impact of pain on overall survival in patients with cancer. Supportive care in cancer\u202f: official journal of the Multinational Association of Supportive Care in Cancer. 2017;25(5):1687\u201398.","journal-title":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"3","key":"2210_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00228-019-02801-2","volume":"76","author":"JW Boland","year":"2020","unstructured":"Boland JW, Allgar V, Boland EG, Bennett MI, Kaasa S, Hjermstad MJ, Johnson M. The relationship between pain, analgesics and survival in patients with advanced cancer; a secondary data analysis of the international European palliative care Cancer symptom study. Eur J Clin Pharmacol. 2020;76(3):393\u2013402.","journal-title":"Eur J Clin Pharmacol"},{"key":"2210_CR16","unstructured":"Zheng Zhendong in the Ming army Xie Xiaodong Hao Hui Chen Xiaoxia Liu Yongye Qu Shuxian Ding Zhenyu. A prospective study of the survival of 983 patients with advanced cancer pain. Proceedings and Lectures of the 7th National Congress of Cancer Rehabilitation and Palliative Medicine. 2011."},{"issue":"1","key":"2210_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1046\/j.1526-4637.2001.002001028.x","volume":"2","author":"PS Staats","year":"2001","unstructured":"Staats PS, Hekmat H, Sauter P, Lillemoe K. The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a double-blind, randomized, placebo-controlled study. Pain medicine (Malden, Mass). 2001;2(1):28\u201334.","journal-title":"Pain medicine (Malden, Mass)"},{"issue":"6","key":"2210_CR18","doi-asserted-by":"publisher","first-page":"e971","DOI":"10.1002\/onco.13796","volume":"26","author":"AL Coveler","year":"2021","unstructured":"Coveler AL, Mizrahi J, Eastman B, Apisarnthanarax SJ, Dalal S, McNearney T, Pant S. Pancreas Cancer-Associated Pain Management. Oncologist. 2021;26(6):e971\u201382.","journal-title":"Oncologist"},{"issue":"1","key":"2210_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12943-019-1073-4","volume":"18","author":"S Peng","year":"2019","unstructured":"Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K, Nishiyama A, Arai S, Yano S, Wang W. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 2019;18(1):165.","journal-title":"Mol Cancer"},{"issue":"6","key":"2210_CR20","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1158\/2159-8290.CD-20-1312","volume":"11","author":"D Salas-Benito","year":"2021","unstructured":"Salas-Benito D, P\u00e9rez-Gracia JL, Ponz-Sarvis\u00e9 M, Rodriguez-Ruiz ME, Mart\u00ednez-Forero I, Casta\u00f1\u00f3n E, L\u00f3pez-Picazo JM, Sanmamed MF, Melero I. Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discov. 2021;11(6):1353\u201367.","journal-title":"Cancer Discov"},{"issue":"2","key":"2210_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/17425247.2021.1825376","volume":"18","author":"Y Xue","year":"2021","unstructured":"Xue Y, Gao S, Gou J, Yin T, He H, Wang Y, Zhang Y, Tang X, Wu R. Platinum-based chemotherapy in combination with PD-1\/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. Expert Opin Drug Deliv. 2021;18(2):187\u2013203.","journal-title":"Expert Opin Drug Deliv"},{"key":"2210_CR22","doi-asserted-by":"publisher","first-page":"105194","DOI":"10.1016\/j.phrs.2020.105194","volume":"160","author":"ZQ Li","year":"2020","unstructured":"Li ZQ, Yan HC, Gu JJ, Yang YL, Zhang MK, Fang XJ. Comparative efficacy and safety of PD-1\/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials. Pharmacol Res. 2020;160:105194.","journal-title":"Pharmacol Res"},{"key":"2210_CR23","doi-asserted-by":"publisher","first-page":"825338","DOI":"10.3389\/fmicb.2022.825338","volume":"13","author":"WK Mousa","year":"2022","unstructured":"Mousa WK, Chehadeh F, Husband S. Recent Advances in Understanding the Structure and Function of the Human Microbiome. Front Microbiol. 2022;13:825338.","journal-title":"Front Microbiol"},{"issue":"1","key":"2210_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41575-018-0061-2","volume":"16","author":"N Zmora","year":"2019","unstructured":"Zmora N, Suez J, Elinav E. You are what you eat: diet, health and the gut microbiota. Nat Rev Gastroenterol Hepatol. 2019;16(1):35\u201356.","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-02210-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-02210-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-02210-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T15:04:08Z","timestamp":1669129448000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-02210-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2210"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-02210-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"25 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As the retrospective nature of our study, we contacted patients by telephone to obtain informed consent from them and made telephone recordings. The Ethical Committee of Third Hospital of Shanxi Medical University reviewed the telephone recordings and approved our study (Ethics No. SBQKL-2022\u2013111). All methods were performed in accordance with the relevant guidelines and regulations. All participants gave informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"431"}}